The 3 Rs concept, which was developed by Russell and Burch in 1959, was implemented into the legal framework in the European Union (EU) for the protection of vertebrate animals used for experimental and other scientific purposes, when Directive 86/609/EEC was adopted in 1986. To reduce or replace animal testing for regulatory purposes, nonanimal tests must be independently validated to prove that they can provide information that is relevant and reliable for hazard prediction in vivo. At the end of the 1980s, no scientific concept existed for the formal validation of in vitro toxicity tests, so a small group of European and American scientists developed a set of principles for experimental validation, which was accepted internationally by the OECD in 1996. A major breakthrough was the acceptance in the EU of the scientifically validated in vitro toxicity test for phototoxic potential in 2000, which was accepted by the OECD at the worldwide level in 2002. Taking the progress in the development and validation of alternative toxicity tests during the past decade into account, the current concepts of developing alternatives to the standard 2-year rodent bioassay for carcinogenicity testing are discussed.
INTRODUCTION
In 1959, William Russell and Rex Burch published their book, The Principles of Humane Experimental Technique (16) , in which they put forward the 3 Rs concept (reduction, refinement, and replacement) in relation to the humane treatment of experimental animals. Today the 3 Rs concept has become the generally accepted scientific basis of institutions serving the development of alternatives to animal experiments, such as in Germany ZEBET (Zentralstelle zur Erfassung und Bewertung von Ersatz-und Ergänzungsmethoden zum Tierversuch, Berlin, Germany), in Europe ECVAM (European Centre for the Validation of Alternative Methods, Ispra, Italy), and in the USA ICCVAM (Interagency Coordinating Center for the Validation of Alternative Methods, Research Triangle Park, North Carolina). In regulatory toxicology, animal tests are used in hazard assessment to identify the toxicological properties of chemicals to which humans or the environment are exposed, when the chemicals are used in a specific product or for a specific purpose.
The exposure of laboratory animals to hazardous chemicals in safety testing of drugs and other chemical entities may lead to considerable suffering and even death of the animals. To reduce the suffering of laboratory animals for regulatory purposes, the 3 Rs concept has successfully been applied. The harmonization of test guidelines at the international level has proven to reduce testing in animals significantly. In contrast, it is a more difficult task to replace a given animal test that is used for regulatory purposes and to provide the same information required for the safety assessment of chemicals. Meanwhile there are a few examples, which prove that regulatory animal tests can be replaced, when the mechanistic basis of the specific area of toxicology is well understood.
Using the validation of the 3T3 NRU in vitro phototoxicity test as an example, it will be illustrated that experimentally validated nonanimal tests have been accepted for regulatory purposes by EU Member States, by the US regulatory agencies, and in the year 2002 even at a worldwide level by the OECD.
Carcinogenicity testing today normally includes 2-year studies in rats and mice of both sexes, following widely accepted standardized procedures. These studies are usually preceded by tests for genetic toxicity and subchronic toxicity studies to select dose levels for 2-year studies. Although these data are used for quantitative risk assessment, the mechanistic basis is usually unknown. The series of studies is very expensive and requires 5 years or more to be conducted. Alternative approaches are being developed that would provide more mechanistic information and hopefully would permit decisions to be made about carcinogenic potential without the necessity to conduct 2-year studies in rats and mice of both sexes. Decisions could be based on a profile of data rather than on the results of one test. Procedures for regulatory acceptance of new approaches for carcinogenicity testing are critical to future progress.
Legal Framework in Europe for Developing Alternatives to Experimental Animals
According to article 7.2 of EU Directive 86/609/EEC (10) on the use of experimental animals "an experiment shall not be performed if another scientifically satisfactory method of obtaining the result sought, not entailing the use of an animal, is reasonably and practicably available." Moreover, in the same directive it is proposed in article 23 that "the Commission and Member States should encourage research into the development and validation of alternative techniques which could provide the same level of information as that obtained in experiments using animals, but which involve fewer animals or which entail less painful procedures, and shall take such other steps as they consider appropriate to encourage 54 0192-6233/03$3.00+$0.00 To give an example of the duties assigned to validation centres, the national German centre ZEBET has to serve the following mission: r to fund research on alternatives; r to coordinate validation studies; r to cooperate with national and international funding agencies and validation centres; r to provide a forum for information on alternatives to animal testing. Because ZEBET is serving the federal ministers of health, environment, research and consumer protection, and agriculture, reduction of testing in animals for regulatory purposes is ZEBET's main task. The EU validation centre ECVAM is also focussing its activity on reducing regulatory safety testing in animals and the US validation agency ICCVAM is serving a similar mission. ECVAM and ZEBET have funds to support the development and validation of alternative methods, while ICCVAM has so far limited its activity to scientifically evaluate the results of validation studies conducted outside the United States of America.
Decrease in Experimental Animal Numbers During the Past Decade in Europe as Illustrated by the Situation in Germany
EU Directive 86/609/EEC has for the first time allowed government authorities in EU Member States to collect test animal numbers according to a standardized procedure. Since ZEBET was established in 1989, the annual numbers of experimental animals in Germany have decreased from 2.7 million in 1989 to 1.6 million in the year 1999. A closer analysis shows that the decrease was predominantly due to a reduction in animal numbers used for the development of drugs, which went down by more than 50% in 10 years, from 1.4 million in 1989 to 0.6 million. in 2000. The decrease is even more impressive, when taking into account earlier data provided by the German association of drug manufacturers, which show that in 1977 4.4 Mio. experimental animals had been used for the development and safety testing of new drugs in Germany (Figure 1 ).
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This dramatic development is not due to the high priority the EU Directive gives to the development of in vitro alternatives but to a general change of the methodology in the life sciences from animal models to molecular biology and genetics including cell and tissue culture models. In the field of drug development the new technology allows high throughput screening (HTS) of thousands of new drug candidates. This approach is, of course, faster and cheaper than animal models. However, at the same time it has proven extremely difficult to reduce animal numbers in regulatory testing, as the established endpoints in toxicity tests in laboratory animals are usually organ specific and cover endpoints that are quite similar to the situation in humans.
Use of Animal Data in the Safety Assessment of Chemicals
It is the goal of regulatory toxicology in the field of chemicals to ensure the occupational safety of workers in the process of producing chemicals, to ensure the safety of food and beverages, to protect patients against possible hazards represented by drugs and medical devices, and to protect humans and the environment against possible hazards posed by residues of chemicals, eg, pesticides. The standard approach in regulatory toxicology to assess the toxicity of chemicals is the determination of toxic properties in standardised animal tests, as described in the OECD Guidelines for Testing of Chemicals (13) . This information is then used by regulators to classify each chemical according to internationally harmonised guidelines in the first step, eg, as harmful, toxic, irritant, then to label them in the second step according to EU risk (R) phrases (4), eg, "R-41: risk of serious damage to the eye." The consequences of classification and labelling are the restricted use of the tested chemical in finished products (depending on exposure), and safety and labelling recommendations.
Reducing Animal Numbers in Regulatory Testing by International Harmonisation of Test Guidelines
For the past 30-40 years, toxicity testing has been developed empirically in many laboratories around the world. Table 1 gives a summary of toxicity tests, which are required for regulatory purposes today. For a given specific area of toxicology, eg, eye and skin irritation or embryotoxicity, the standard animal procedures differed considerably between countries, eg, as far as species, regimen of treatment, numbers of animals per treatment group etc. In addition, the way (10) was the first, and so far, the most effective step in reducing duplication of testing in animals for regulatory purposes, because a toxicity test conducted according to the OECD guidelines will be accepted by regulatory agencies in all OECD Member States. These Member States are the world's major industrial nations. A similar approach has thereafter been used for the safety and efficacy testing of drugs by the International Conference on Harmonisation (ICH) (7) , which represents the 3 major economic regions, namely Europe, Japan, and the USA. Since 1990, the ICH has accepted harmonised guidelines for efficacy and safety testing of drugs and medicines, including animal tests. Again, the harmonisation of test guidelines has led to significant reduction of testing in animals, because regulatory agencies around the world now accept the results of a test conducted according to ICH guidelines. Table 2 summarises the most important areas, which require safety testing in animals, and in which the test guidelines have been harmonised at the international level. Table 2 shows that in addition to drugs, industrial chemicals, and pesticides, international test guidelines have also been harmonised for hormones and biologicals by the pharmacopoeias and for vaccines by the WHO. So far the harmonisation of international test guidelines for toxicity and safety testing has been the most successful approach to reduce animal testing for regulatory purposes.
Principles of Scientific Validation: The Amden Validation Workshops
Regulators will only accept alternatives to animal tests in toxicology, if the new tests will allow them to classify and label chemicals in the same way as the current animal tests. The OECD has therefore decided that in vitro toxicity tests can be accepted for regulatory purposes only after a successful experimental validation study. To approach this problem scientifically, European and American scientists agreed in 1990 in Amden, Switzerland, on a definition of experimental validation and the essential steps in this process. At this workshop, validation was defined as the process by which reproducibility and relevance of a toxicity testing procedure are established for a particular purpose (3), regardless of whether the method is an in vitro or in vivo test. The essential steps of the experimental validation process were defined in the following manner: Steps 2 and 3 are the essential part of a formal validation study conducted for regulatory purposes. The report of the 1st Amden workshop on validation (2) encouraged scientists to initiate several international validation studies. Because the Draize eye test has been the most widely criticised toxicity test, a worldwide validation study on 9 alternatives to the Draize eye test was coordinated by the EU and the British Home Office. However this and other extensive international validation attempts failed (4) .
Therefore, the leading scientists involved met for a 2nd validation workshop in Amden in 1994 to improve the concept of the validation procedure. The 2nd Amden validation work-shop recommended the inclusion of new elements into the validation process (3), which had not sufficiently been identified in the 1st Amden validation workshop. The following 3 essential elements were recommended.
1. The definition of a biostatistically based prediction model; 2. the inclusion of a prevalidation stage between test development and formal validation under blind conditions; and 3. a well-defined management structure.
As to in vitro tests, a prediction model should allow the prediction of in vivo endpoints in animals or humans from the endpoints determined. The prediction model must be defined mathematically in the standard operation procedure of the test that will undergo experimental validation under blind conditions with coded chemicals (3) . In order to assess the limitations of a new test before it will be evaluated in a validation study, the test should be standardised in a prevalidation study with a few test chemicals in a few laboratories (6) . This will ensure that the in vitro test method, including the prediction model, is robust and that the formal validation study with coded chemicals is likely to be successful. Finally, the goal of a validation study has to be defined clearly, and the management structure has to ensure that within the study the scientists who are responsible for essential tasks can conduct their duties independently from the sponsors and the managers of the study, eg, biostatistical analysis, and the selection, coding and shipment of the test chemicals.
The improved concept of experimental validation for regulatory purposes defined in the 2nd Amden workshop was accepted by ECVAM, in 1995, and in 1996 by US regulatory agencies (12) and also by the OECD (14) . After this agreement at the international level, scientists have tried to follow the ECVAM/US/OECD principles for validation in new validation trials. The improved validation concept was immediately introduced into ongoing validation studies, eg, the ECVAM/COLIPA validation study on in vitro phototoxicity tests and the ECVAM validation study of in vitro skin corrosivity test.
Regulatory Acceptance of the Successfully Validated 3T3 NRU In Vitro Phototoxicity Test at a Worldwide Level by the OECD in 2000
Since no standard guideline for the testing of photoirritation potential, either in vivo or in vitro, had been accepted for regulatory purposes at the international level by the OECD, in 1991, the European Commission (EC) and the European Cosmetics, Toiletry, and Perfumery Association (COLIPA) established a joint programme to develop and validate in vitro photoirritation tests. In the first phase of the study, which was funded by DG XI of the EC and coordinated by ZEBET, in vitro phototoxicity tests established in laboratories of the cosmetics industry were evaluated and also a new assay, the 3T3 NRU PT test, which is a photocytotoxicity test using the mouse fibroblast cell line 3T3 and neutral red uptake (NRU) as the endpoint for cytotoxicity.
In the prevalidation study conducted with 20 test chemicals quite unexpectedly, the 3T3 NRU PT in vitro phototoxicity test was the only in vitro test in which all of the 20 test chemicals were correctly identified as phototoxic or nonphototoxic (18) . Quite independently, a laboratory in Japan subsequently obtained the same correct results in the 3T3 NRU PT, when testing the same set of 20 test chemicals.
In the second phase of the study, which was funded by ECVAM and coordinated by ZEBET, the 3T3 NRU PT test was validated with 30 carefully selected test chemicals in 11 laboratories in a blind trial. A representative set of test chemicals covering all major classes of phototoxins was selected according to results from standardised photopatch testing in humans (21) . The results obtained in this in vitro test under blind conditions were reproducible, and the correlation between in vitro and in vivo data was almost perfect (20) . Therefore, the ECVAM Scientific Advisory Committee (ESAC) concluded in 1998, that the 3T3 NRU PT is a scientifically validated test which is ready to be considered for regulatory acceptance (8) . However, the EU expert committee on the safety of cosmetics, the Scientific Committee on Cosmetology and Non-Food-Products (SCCNFP), criticised that an insufficient number of UV-filter chemicals (widely used as sunblockers) were tested in the formal validation study. In a subsequent blind trial on UV filter chemicals, which was again funded by ECVAM and coordinated by ZEBET, the phototoxic potential of all test chemicals was predicted correctly in the 3T3 NRU PT in vitro phototoxicity test (19) . Therefore, in 1998, the EU, having accepted the 3T3 NRU PT test as the first experimentally validated in vitro toxicity test for regulatory purposes, officially applied to the OECD for worldwide acceptance of this in vitro toxicity test. Early in 2000 the European Commission has officially accepted and published the 3T3 NRU PT phototoxicity test in Annex V of Directive 67/548 EEC on the Classification, Packaging and Labelling of Dangerous Substances (11) . Thus, this in vitro test is the first formally validated in vitro toxicity test that has been accepted into Annex V, and it is the only phototoxicity that is accepted for regulatory purposes in Europe. Meanwhile, in the year 2002 the OECD has accepted the 3T3 NRU PT phototoxicity test at the worldwide level as the first in vitro toxicity test into the OECD Guidelines for the testing of chemicals (15) .
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ALTERNATIVE TESTS FOR CARCINOGENIC PROPERTIES Review of the 2-Year Rodent Studies
There are a number of often cited reasons for desirable changes of this approach that are obvious, such as the pressure of costs of 2-year studies, the large numbers of animals required, the long duration of the studies, and the uncertainty of the outcome in terms of equivocal answers or extrapolation of results to humans. For example, due to the high background incidence of liver tumors in male B6C3F 1 mice, discussions continue on the relevance of this tumor for humans.
There are less obvious reasons that must be considered. Two-year studies in rodents are empirical by nature. It is usually assumed that the development of most tumors is predictive for tumorigenic potential in humans. A well-documented exemption are the kidney tumors in male rats formed due to an accumulation of the α 2 µ-globulin protein and bladder tumors due to the formation of crystals in the urine.
One of the measures of the 2-year study as gold standard is the predictivity between rat and mice. In a recent review of the 2-year rodent carcinogenesis bioassay Schwetz and Gaylor (17) from the US FDA and the US National Center for Toxicological Research concluded that in this assay the prediction for carcinogenicity is about 75% accurate. According to their evaluation the bioassay is poor at the detection of weak carcinogens and not useful for assessing the mechanism of carcinogenesis, which was not anticipated when the bioassay was introduced more than 2 decades ago. Carcinogenic potency is another measure of the usefulness of the 2-year studies. It is defined as the lifetime risk per unit of average daily exposure. Using the NTP database Chen and Gaylor (20) showed that carcinogenic potencies for rats and mice differed generally by a factor of 40. Despite this variability it is usually argued that the correlation of potency between rats and mice supports extrapolation to humans. However, as these studies were only conducted on concordant chemicals, ie, chemicals that produce tumors in both rats and mice, this conclusion is questionable. These limitations do, of course, raise questions on the usefulness of the bioassay as the gold standard from which conclusions on the carcinogenic potential in humans may be drawn.
Alternative Testing Strategies
In recent years, scientists in the US FDA and also in regulatory agencies in Europe have argued that conclusions on carcinogenic potential of chemicals should not only be based on the results of the long-term bioassay, but consider the whole profile of toxicological data, and include mechanistic considerations. Such information may be provided by studies on transgenic animal models, although the relevance of these models for carcinogenesis in humans has still to be critically evaluated (22) .
The first step in the development of alternative tests is the suspision that there is human exposure and, therefore, a desire to collect information on carcinogenic potential. First estimates would be based on physicochemical properties of the compound, structural alert information, information from computer-based prediction systems, and the results of the genetic toxicity screen. From this information the conclusion can be drawn that a chemical is either nongenotoxic or genotoxic. If the compound is strongly genotoxic, one might anticipate that it is a carcinogen without further testing in the 2-year carcinogenesis bioassay. However, as one third of the mutagens are not carcinogens in the standard bioassay, and about one third of the carcinogens are not mutagenic in common tests, it appears to be mandatory to proceed with the 2-year rodent study for the time being. For substances that are nongenotoxic, one may proceed to the newborn mouse assay or the transgenic TG:AC mouse model (22) . If a nongenotoxic chemical is positive in either the TG:AC or the newborn mouse assay, one has the option to conduct a 2-year study or to presume that the compound is positive, in particular if there is additional mechanistic evidence for nongenotoxic carcinogenicity.
The new testing strategy based on medium-term carcinogenesis, must also include information related to nongenotoxic mechanisms of carcinogenicity. This includes data on mechanisms described in Table 3 , eg, modulation of target cells by hormones, perturbation by growth factors, changes in cell proliferation, apoptosis, and other mechanisms of carcinogenicity that do not depend on primary damage to DNA.
One way to facilitate the acceptance of new test systems would be to compare their results with those of the traditional 2-year bioassay. Another factor influencing the acceptance of alternative test systems is the level of confidence that is currently placed on negative 2-year rodent studies. A major concern about acceptence of alternative test systems is how regulatory agencies will use either positive or negative results from these tests. We have to consider whether to rely exclusively on the results of the 2-year rodent carcinogenesis bioassay or to partially replace this approach by alternative studies such as medium-term carcinogenesis bioassays, which appear to be reliable in case of positive results but are not applicable when negative results are obtained.
CONCLUSIONS
The successful validation and regulatory acceptance of several in vitro toxicity test in the European Union proves that the validation procedure recommended by ECVAM (3) and the OECD (14) is most appropriate for the validation of in vitro toxicity tests.
As far as alternatives to the 2-year rodent carcinogenesis bioassay are concerned, we have to recognise that this test is not perfect. Therefore, results of alternative tests should not be evaluated against the 2-year bioassay but on their own merit. We are in a period of transition during which the results of short-term tests, in combination with the results of the 2-year carcinogenesis bioassay, will provide the opportunity to evaluate the performance of the new medium-term carcinogenesis bioassays. Recommendations of the International Committee of Harmonisation (ICH) to accept carcinogenicity data in 1 species and other test systems as an alternative to data from 2 rodent species demonstrate that at least for drugs there is a need to change the requirements for carcinogenicity data.
